These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

393 related articles for article (PubMed ID: 30828317)

  • 41. Inhibition of the activity of dipeptidyl-peptidase IV as a treatment for type 2 diabetes.
    Holst JJ; Deacon CF
    Diabetes; 1998 Nov; 47(11):1663-70. PubMed ID: 9792533
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Dipeptidyl peptidase-4 (DPP-4): Localization and activity in human and rodent islets.
    Liu L; Omar B; Marchetti P; Ahrén B
    Biochem Biophys Res Commun; 2014 Oct; 453(3):398-404. PubMed ID: 25268763
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Implementation of GLP-1 based therapy of type 2 diabetes mellitus using DPP-IV inhibitors.
    Holst JJ
    Adv Exp Med Biol; 2003; 524():263-79. PubMed ID: 12675249
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Ezetimibe stimulates intestinal glucagon-like peptide 1 secretion via the MEK/ERK pathway rather than dipeptidyl peptidase 4 inhibition.
    Chang E; Kim L; Choi JM; Park SE; Rhee EJ; Lee WY; Oh KW; Park SW; Park DI; Park CY
    Metabolism; 2015 May; 64(5):633-41. PubMed ID: 25704082
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Beyond glucose lowering: glucagon-like peptide-1 receptor agonists, body weight and the cardiovascular system.
    Vergès B; Bonnard C; Renard E
    Diabetes Metab; 2011 Dec; 37(6):477-88. PubMed ID: 21871831
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Localization of dipeptidyl peptidase-4 (CD26) to human pancreatic ducts and islet alpha cells.
    Augstein P; Naselli G; Loudovaris T; Hawthorne WJ; Campbell P; Bandala-Sanchez E; Rogers K; Heinke P; Thomas HE; Kay TW; Harrison LC
    Diabetes Res Clin Pract; 2015 Dec; 110(3):291-300. PubMed ID: 26515908
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes.
    Herman GA; Bergman A; Stevens C; Kotey P; Yi B; Zhao P; Dietrich B; Golor G; Schrodter A; Keymeulen B; Lasseter KC; Kipnes MS; Snyder K; Hilliard D; Tanen M; Cilissen C; De Smet M; de Lepeleire I; Van Dyck K; Wang AQ; Zeng W; Davies MJ; Tanaka W; Holst JJ; Deacon CF; Gottesdiener KM; Wagner JA
    J Clin Endocrinol Metab; 2006 Nov; 91(11):4612-9. PubMed ID: 16912128
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Dipeptidyl peptidase IV inhibitors and the incretin system in type 2 diabetes mellitus.
    Langley AK; Suffoletta TJ; Jennings HR
    Pharmacotherapy; 2007 Aug; 27(8):1163-80. PubMed ID: 17655515
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Cardiovascular effects of DPP-4 inhibition: beyond GLP-1.
    Fadini GP; Avogaro A
    Vascul Pharmacol; 2011; 55(1-3):10-6. PubMed ID: 21664294
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Twelve weeks treatment with the DPP-4 inhibitor, sitagliptin, prevents degradation of peptide YY and improves glucose and non-glucose induced insulin secretion in patients with type 2 diabetes mellitus.
    Aaboe K; Knop FK; Vilsbøll T; Deacon CF; Holst JJ; Madsbad S; Krarup T
    Diabetes Obes Metab; 2010 Apr; 12(4):323-33. PubMed ID: 20380653
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Inhibition of dipeptidyl peptidase-4 augments insulin secretion in response to exogenously administered glucagon-like peptide-1, glucose-dependent insulinotropic polypeptide, pituitary adenylate cyclase-activating polypeptide, and gastrin-releasing peptide in mice.
    Ahrén B; Hughes TE
    Endocrinology; 2005 Apr; 146(4):2055-9. PubMed ID: 15604213
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The incretin system ABCs in obesity and diabetes - novel therapeutic strategies for weight loss and beyond.
    João AL; Reis F; Fernandes R
    Obes Rev; 2016 Jul; 17(7):553-72. PubMed ID: 27125902
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The islet enhancer vildagliptin: mechanisms of improved glucose metabolism.
    Ahrén B; Foley JE
    Int J Clin Pract Suppl; 2008 Mar; (159):8-14. PubMed ID: 18269436
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Differentiating incretin-based therapies for population-based health care.
    Calabrese D
    Am J Manag Care; 2011 Mar; 17(2 Suppl):S52-8. PubMed ID: 21517657
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Incretins and other peptides in the treatment of diabetes.
    Todd JF; Bloom SR
    Diabet Med; 2007 Mar; 24(3):223-32. PubMed ID: 17263764
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Mechanisms of Cardiovascular Injury in Type 2 Diabetes and Potential Effects of Dipeptidyl Peptidase-4 Inhibition.
    Dokken B
    J Cardiovasc Nurs; 2016; 31(3):274-83. PubMed ID: 25829138
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Dipeptidyl peptidase-4 inhibitor ameliorates early renal injury through its anti-inflammatory action in a rat model of type 1 diabetes.
    Kodera R; Shikata K; Takatsuka T; Oda K; Miyamoto S; Kajitani N; Hirota D; Ono T; Usui HK; Makino H
    Biochem Biophys Res Commun; 2014 Jan; 443(3):828-33. PubMed ID: 24342619
    [TBL] [Abstract][Full Text] [Related]  

  • 58. DPP-4 is expressed in human pancreatic beta cells and its direct inhibition improves beta cell function and survival in type 2 diabetes.
    Bugliani M; Syed F; Paula FMM; Omar BA; Suleiman M; Mossuto S; Grano F; Cardarelli F; Boggi U; Vistoli F; Filipponi F; De Simone P; Marselli L; De Tata V; Ahren B; Eizirik DL; Marchetti P
    Mol Cell Endocrinol; 2018 Sep; 473():186-193. PubMed ID: 29409957
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Pancreatic α Cell-Derived Glucagon-Related Peptides Are Required for β Cell Adaptation and Glucose Homeostasis.
    Traub S; Meier DT; Schulze F; Dror E; Nordmann TM; Goetz N; Koch N; Dalmas E; Stawiski M; Makshana V; Thorel F; Herrera PL; Böni-Schnetzler M; Donath MY
    Cell Rep; 2017 Mar; 18(13):3192-3203. PubMed ID: 28355570
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Cardiovascular Actions and Clinical Outcomes With Glucagon-Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors.
    Nauck MA; Meier JJ; Cavender MA; Abd El Aziz M; Drucker DJ
    Circulation; 2017 Aug; 136(9):849-870. PubMed ID: 28847797
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.